Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.
Frequently asked questions
What sector does Gabather AB (publ) (GABA) operate in?
Gabather AB (publ) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Gabather AB (publ) (GABA) current stock price?
As of the latest data, Gabather AB (publ) stock price is SEK 0.03, with a previous close of SEK 0.03. Gabather AB (publ) lost -SEK 0.00 in the last trading session, representing a -0.59% loss.
What is Gabather AB (publ) (GABA) current market capitalization?
Gabather AB (publ) market cap is approximately 20.51 million.
What is Gabather AB (publ) (GABA) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.01.
What is Gabather AB (publ) (GABA) EBITDA?
Gabather AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -1.08 million.
Does Gabather AB (publ) (GABA) pay dividends?
No. Gabather AB (publ) does not pay a dividend.
What is Gabather AB (publ) (GABA) beta (volatility) score?
Gabather AB (publ) has a beta of -0.765, indicating lower volatility than the overall market.